יתרות מזומנים למניה אחת atricure.com (ATRC)

The active development of minimally invasive technologies and AtriClip clinical trials create growth potential, as evidenced by the liquid assets per share of AtriCure, Inc. (ATRC). The 3.67 level captures the current state of financial stability. Stability is ensured by in-house manufacturing plants in the US with strict assembly control, while operational efficiency is supported by specialized sterile instrument delivery timed precisely for the moment of surgery.
פילוחים אנליטיים של חברת AtriCure, Inc. (ATRC)

AtriCure, Inc. (ATRC) incurs high development costs for ablation systems that require significant capital, which is partially offset by high-margin sales of consumables. This trend is reflected in the ratio of total liquid assets to the number of shares outstanding, allowing an analysis of cash per share to assess the company's ability to fund growth without incurring new debt obligations.